| Business Summary | | Theragenics
Corporation
is
the
manufacturer
of
TheraSeed,
a
rice-sized
device
used
primarily
in
treating
localized
prostate
cancer
with
a
one-time,
minimally
invasive
procedure.
Theragenics
is
the
world's
leading
producer
of
palladium-103
(Pd-103),
the
radioactive
isotope
that
supplies
the
therapeutic
radiation
for
its
TheraSeed
implant.
Theragenics
is
also
involved
in
research
and
development
utilizing
Pd-103
for
the
treatment
of
restenosis,
macular
degeneration
and
other
diseases,
and
has
research
and
development
programs
involving
other
isotopes
and
their
uses.
Physicians,
hospitals
and
other
healthcare
providers,
primarily
located
in
the
United
States,
utilize
the
TheraSeed
product. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Theragenics
Corporation
develops,
manufactures,
and
markets
radiological,
pharmaceuticals
and
devices
used
in
the
treatment
of
cancer.
For
the
six
months
ended
6/30/01,
revenues
rose
17%
to
$26.7
million.
Net
income
rose
6%
to
$8.6
million.
Revenues
reflect
increased
average
selling
prices
of
TheraSeed(R).
Earnings
were
partially
offset
by
costs
associated
with
three
additional
cyclotrons
in
operation
and
costs
associated
with
the
Indigo
Agreement. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| M. Christine Jacobs, 50 Pres,
CEO and Chairman | $568K | $192K | Bruce Smith, 48 CFO,
Exec. VP, Treasurer, Sec. | 198K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|